Novavax Current Ratio 2006-2021 | NVAX

Current and historical current ratio for Novavax (NVAX) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Novavax current ratio for the three months ending June 30, 2021 was 1.43.
Novavax Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $2.36B $1.65B 1.43
2021-03-31 $2.25B $1.21B 1.86
2020-12-31 $1.25B $0.58B 2.15
2020-09-30 $0.67B $0.24B 2.81
2020-06-30 $0.64B $0.21B 2.98
2020-03-31 $0.26B $0.02B 13.45
2019-12-31 $0.10B $0.03B 3.77
2019-09-30 $0.09B $0.02B 4.13
2019-06-30 $0.11B $0.04B 2.66
2019-03-31 $0.12B $0.03B 3.92
2018-12-31 $0.12B $0.05B 2.62
2018-09-30 $0.16B $0.05B 3.44
2018-06-30 $0.19B $0.04B 4.52
2018-03-31 $0.18B $0.05B 4.03
2017-12-31 $0.20B $0.07B 2.76
2017-09-30 $0.23B $0.07B 3.31
2017-06-30 $0.24B $0.07B 3.54
2017-03-31 $0.26B $0.06B 4.57
2016-12-31 $0.29B $0.07B 4.33
2016-09-30 $0.35B $0.08B 4.68
2016-06-30 $0.42B $0.08B 5.13
2016-03-31 $0.49B $0.07B 6.82
2015-12-31 $0.29B $0.08B 3.76
2015-09-30 $0.31B $0.03B 12.47
2015-06-30 $0.33B $0.03B 12.31
2015-03-31 $0.35B $0.03B 12.17
2014-12-31 $0.19B $0.03B 5.52
2014-09-30 $0.19B $0.02B 10.30
2014-06-30 $0.17B $0.02B 9.53
2014-03-31 $0.13B $0.01B 9.40
2013-12-31 $0.15B $0.02B 8.00
2013-09-30 $0.16B $0.01B 10.87
2013-06-30 $0.05B $0.01B 4.03
2013-03-31 $0.05B $0.01B 5.59
2012-12-31 $0.05B $0.01B 4.32
2012-09-30 $0.04B $0.01B 3.49
2012-06-30 $0.04B $0.01B 3.71
2012-03-31 $0.03B $0.01B 3.37
2011-12-31 $0.03B $0.01B 3.45
2011-09-30 $0.03B $0.01B 3.90
2011-06-30 $0.03B $0.01B 3.16
2011-03-31 $0.03B $0.01B 2.60
2010-12-31 $0.03B $0.01B 3.25
2010-09-30 $0.04B $0.01B 3.97
2010-06-30 $0.03B $0.01B 3.24
2010-03-31 $0.03B $0.01B 3.66
2009-12-31 $0.05B $0.01B 5.54
2009-09-30 $0.04B $0.01B 6.19
2009-06-30 $0.03B $0.01B 3.14
2009-03-31 $0.03B $0.03B 0.99
2008-12-31 $0.04B $0.03B 1.27
2008-09-30 $0.05B $0.03B 1.55
2008-06-30 $0.04B $0.01B 4.24
2008-03-31 $0.04B $0.01B 5.17
2007-12-31 $0.05B $0.01B 7.90
2007-09-30 $0.06B $0.01B 9.85
2007-06-30 $0.06B $0.01B 11.25
2007-03-31 $0.07B $0.01B 12.53
2006-12-31 $0.08B $0.01B 14.49
2006-09-30 $0.08B $0.00B 22.15
2006-06-30 $0.08B $0.00B 20.95
2006-03-31 $0.09B $0.00B 25.25
2005-12-31 $0.04B $0.01B 7.71
2005-09-30 $0.01B $0.01B 2.27
2005-06-30 $0.01B $0.01B 1.48
2005-03-31 $0.01B $0.01B 2.21
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.023B $0.476B
NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76